SYNTHETIC CONJUGATED ESTROGENS A
Clinical safety rating: avoid
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
Synthetic conjugated estrogens bind to estrogen receptors (ERα and ERβ) in target tissues, activating genomic and non-genomic signaling pathways that regulate gene transcription and cellular functions.
| Metabolism | Primarily hepatically metabolized by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9) and conjugation with glucuronide and sulfate. Enterohepatic recirculation occurs. |
| Excretion | Renal excretion of conjugated metabolites accounts for approximately 50-80% of elimination. Fecal/biliary excretion is minor (<10%). |
| Half-life | Terminal elimination half-life is 13-27 hours for estrone conjugates, allowing once-daily dosing. |
| Protein binding | Approximately 95% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Apparent Vd is 2-4 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Oral bioavailability is 30-50% due to first-pass metabolism. |
| Onset of Action | Oral: 2-4 weeks for therapeutic effects on vasomotor symptoms; effects on vaginal epithelium may appear within 2 weeks. |
| Duration of Action | Duration is approximately 24 hours with daily dosing; effects on bone mineral density require continuous therapy of months to years. |
| Molecular Weight | 288.4 |
0.3 mg orally once daily
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment, reduce dose by 50%. |
| Pediatric use | Not indicated for use in pediatric patients |
| Geriatric use | Use lowest effective dose; monitor for thromboembolic events and malignancy risk |
| 1st trimester | Contraindicated due to risk of fetal harm; use only if clearly needed and no alternative. |
| 2nd trimester | Contraindicated; potential adverse effects on fetal development. |
| 3rd trimester | Contraindicated; may cause fetal harm and complications. |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| FDA category | Positive |
| Placental transfer | Crosses placenta; detected in fetal tissues. Limited human data but animal studies show transfer. |
| Breastfeeding | Excreted into human milk in small amounts; may reduce milk production and quality. Use caution, especially with high doses. Recommend alternative therapy if possible. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer. Unopposed estrogen therapy in women with a uterus is associated with increased risk of endometrial hyperplasia and carcinoma. Estrogen-alone therapy may increase risk of invasive breast cancer. Estrogen plus progestin therapy increases risk of breast cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction.
| Common Effects | osteoporosis prevention |
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive or history of venous thromboembolismActive or history of arterial thromboembolismHypersensitivity to synthetic conjugated estrogens
| Precautions | Cardiovascular disorders: increased risk of stroke, DVT, and MI, Malignant neoplasms: increased risk of endometrial and breast cancer, Gallbladder disease: increased risk, Hypercalcemia: may occur in women with breast cancer and bone metastases, Visual abnormalities: discontinue if sudden partial or complete loss of vision occurs, Hepatic impairment: use with caution in patients with impaired liver function, Fluid retention: monitor patients with conditions that may be exacerbated by fluid retention, Hypothyroidism: estrogen therapy increases thyroid-binding globulin levels, Lipid disorders: may increase triglycerides, Hereditary angioedema: may exacerbate symptoms |
Loading safety data…
| Lactation Rating | L3 - Limited data, use with caution |
| Teratogenic Risk | Category X: contraindicated in pregnancy. First trimester: high risk of fetal urogenital abnormalities, cardiac defects, and limb reduction. Second and third trimesters: associated with vaginal adenosis, clear cell adenocarcinoma in female offspring, and neurodevelopmental delays. Use during pregnancy may cause fetal harm, including spontaneous abortion and congenital malformations. |
| Fetal Monitoring | Not applicable as use is contraindicated in pregnancy. If inadvertent exposure, monitor for fetal growth restriction, congenital anomalies via ultrasound, and maternal blood pressure. Assess fetal heart rate patterns. Long-term follow-up for potential carcinogenesis in offspring recommended. |
| Fertility Effects | Estrogens can interfere with ovulation by inhibiting gonadotropin secretion. May reduce fertility during use; fertility returns upon discontinuation. No long-term effects on fertility reported. Contraceptive-like effects at high doses. |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase estrogen levels; consider limiting intake. Avoid alcohol as it may worsen estrogen-related side effects like nausea. |
| Clinical Pearls | Synthetic conjugated estrogens A (Cenestin) are derived from plant sources and contain a mixture of nine synthetic estrogenic substances. They are bioidentical to human conjugated estrogens. Use the lowest effective dose for the shortest duration. In women with intact uterus, co-administer a progestin to reduce risk of endometrial hyperplasia. Contraindicated in pregnancy, undiagnosed abnormal genital bleeding, known/suspected breast cancer, active venous thromboembolism, and liver disease. Monitor for signs of thromboembolic events and consider transdermal route if concerns exist. |
| Patient Advice | Report any abnormal vaginal bleeding, breast lumps, or pain immediately. · Avoid smoking as it increases risk of serious cardiovascular side effects. · Take with food to reduce nausea if it occurs. · Keep all appointments for regular breast exams, mammograms, and pelvic exams. · Do not use if pregnant or breastfeeding; use effective contraception if needed. · Store at room temperature away from moisture and heat. |